

**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of	)	
	)	
Glenn J. Dorin, <i>et al.</i>	)	Examiner: TBA
	)	
Serial No. TBA	)	Group Art Unit: TBA
	)	
Filed: November 30, 2001	)	Atty. Dkt. No. 012441.00013

For: **Formulation, Solubilization, Purification, and Refolding of Tissue Factor Pathway Inhibitor**

**INFORMATION DISCLOSURE STATEMENT**

The Honorable Assistant Commissioner for  
Patents  
Washington, D.C. 20231

Sir:

Pursuant to their duty of good faith and candor as set forth in 37 C.F.R. § 1.56(a) Applicants submit herewith the references cited on the attached PTO-1449 forms.

Copies of these references are not submitted herewith, but can be found in parent application file U.S. Serial No. 09/443,099.


Applicants respectfully request that the Examiner consider these references in connection with the search of the prior art required by 37 C.F.R. § 1.104.

It is believed that no fee is required to ensure consideration of the cited references by the Examiner. However, if a fee is deemed necessary, the Commissioner is authorized to charge our Deposit Account No. 19-0733.

Respectfully submitted,

BANNER & WITCOFF, LTD.  
1001 G Street, N.W.  
Eleventh Floor  
Washington, D.C. 20001  
Telephone: 202-508-9100  
Dated: November 30, 2001

By: \_\_\_\_\_



Lin J. Hymel  
Registration No. 45,414

<b>PTO-1449 (Modified)</b>  <b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b>	<b>ATTY. DOCKET NO.</b> 012441.00013	<b>SERIAL NUMBER</b> TBA
	<b>APPLICANT</b> Glenn J. Dorin	
	<b>FILING DATE</b> November 30, 2001	<b>GROUP ART UNIT</b> TBA

1000 U.S. PTO  
09/96588  
11/30/01

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	5,212,091	5/18/93	Diaz-Collier et al.			
	5,466,893	11/14/95	Wun et al.			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES/NO
	0 473 564 A1	3/4/92	Europe			
	0 559 632 A2	9/8/93	Europe			
	0 325 691	8/2/89	Europe			
	0 131 864	1/23/85	Europe			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Rainer Rudolph "Successful Protein Folding on a Industrial Scale" Protein Engineering: Principles and Practice, Chapter 10, pages 283-298 -1996
	Rudolph & Lilie "In vitro folding of inclusion body proteins" Folding of Acidic Fibroblast Growth Factor, FASEB J. 10, pgs. 49-56
	Dabora et al. "Effect of Polyanions on the Refolding of Human Acidic Fibroblast Growth Factor*" The Journal of Biological Chemistry, Vol. 266, No. 35, December 15, 1991, pages 23637-23640
	Bernhard Fischer et al. "Isolation, Renaturation, and Formation of Disulfide Bonds of Eukaryotic Proteins Expressed in Escherichia coli as Inclusion Bodies" Biotechnology and Bioengineering, Vol. 41, pages 3-13, (1993)
	J. Harenberg et al. "Tissue factor pathway inhibitor: proposed heparin recognition region" Blood Coagulation and Fibrinolysis, Vol. 6, Suppl. 1, 1995
	Mark E. Gustafson et al. "Renaturation and Purification of Human Tissue Factor Pathway Inhibitor Expressed in Recombinant E. coli" Protein Expression and Purification 5, 233-241 (1994)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet	2	of	2
-------	---	----	---

**Complete if Known**

Application Number	TBA
Filing Date	November 30, 2001
First Named Inventor	Glenn J. Dorin
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	012441.00013

[illegible][illegible]

**Examiner  
Signature**

Date Considered

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

Applicant's unique station designation number (optional). See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.